AYTU BIOPHARMA, INC Finite-Lived Intangible Asset, Expected Amortization, Remainder of Fiscal Year
AYTU BIOPHARMA, INC (AYTU) had Finite-Lived Intangible Asset, Expected Amortization, Remainder of Fiscal Year of $1.09 million as of 2026-03-31, per its 10-Q filed 2026-05-13.
Financial Statements › Notes › Intangible Asset, Finite-Lived, and Capitalized Cost, Software to be Sold, Leased, or Marketed, Estimated Amortization Expense
us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear · last filed 2026-05-13
- 2026-03-31: Finite-Lived Intangible Asset, Expected Amortization, Remainder of Fiscal Year $1.09M.
- 2025-12-31: Finite-Lived Intangible Asset, Expected Amortization, Remainder of Fiscal Year $2.17M.
- 2025-09-30: Finite-Lived Intangible Asset, Expected Amortization, Remainder of Fiscal Year $2.66M.
- 2025-03-31: Finite-Lived Intangible Asset, Expected Amortization, Remainder of Fiscal Year $1.25M.
| Period end | Finite-Lived Intangible Asset, Expected Amortization, Remainder of Fiscal Year |
|---|---|
| 2026-03-31 | $1.09M 10-Q · filed 2026-05-13 |
| 2025-12-31 | $2.17M 10-Q · filed 2026-02-03 |
| 2025-09-30 | $2.66M 10-Q · filed 2025-11-13 |
| 2025-03-31 | $1.25M 10-Q · filed 2025-05-14 |
| 2024-12-31 | $2.50M 10-Q · filed 2025-02-12 |
| 2024-09-30 | $3.74M 10-Q · filed 2024-11-13 |
| 2024-03-31 | $1.63M 10-Q · filed 2024-05-15 |
| 2023-12-31 | $3.26M 10-Q · filed 2024-02-14 |
| 2023-09-30 | $4.89M 10-Q · filed 2023-11-14 |
| 2023-03-31 | $1.52M 10-Q · filed 2023-05-11 |
| 2022-12-31 | $3.04M 10-Q · filed 2023-02-21 |
| 2022-09-30 | $4.56M 10-Q/A · filed 2023-02-21 |
| 2022-03-31 | $1.62M 10-Q · filed 2022-05-16 |
| 2021-12-31 | $3.91M 10-Q · filed 2022-02-14 |
| 2021-09-30 | $5.96M 10-Q · filed 2021-11-15 |
| 2021-03-31 | $2.23M 10-Q · filed 2021-05-17 |
| 2020-12-31 | $3.16M 10-Q · filed 2021-02-11 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| NextCure, Inc. (NXTC) | United States | $0.024B | -0.15 |
| TherapeuticsMD, Inc. (TXMD) | United States | $0.024B | -117.87 |
| ARTELO BIOSCIENCES, INC. (ARTL) | United States | $0.023B | |
| KYNTRA BIO, INC. (KYNB) | United States | $0.028B | 0.17 |
| Transcode Therapeutics, Inc. (RNAZ) | United States | $0.029B | -0.12 |
| Cocrystal Pharma, Inc. (COCP) | United States | $0.022B | |
| Hepion Pharmaceuticals, Inc. (HEPA) | United States | $0.029B | -0.62 |
| ATOSSA THERAPEUTICS, INC. (ATOS) | United States | $0.021B | -0.52 |
| IGC Pharma, Inc. (IGC) | United States | $0.029B | -5.98 |
| Neuphoria Therapeutics Inc. (NEUP) | United States | $0.020B | -1.77 |